Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.2BCash on Hand
93.4mo Cash Runway
Follow ORKA by emailGet an email when ORKA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ORKA, unsubscribe in one click. Privacy
📣 What ORKA Says Is Next
in December 2026 · “In addition, Oruka expects to share 52-week results from EVERLAST-A in December 2026, as well as 52-week results from EVERLAST-B in the second half of 2027.”
Company press release, Oct 26, 2026 · SEC filing
first half of 2027 · ORKA-001: “Pending results from those discussions, Oruka plans to initiate Phase 3 trials of ORKA-001 in moderate-to-severe PsO in the first half of 2027 with the high dose (600 mg).”
Company press release, Oct 26, 2026 · SEC filing
in 2027 · “The Company plans to pursue ORKA-004 in combination with ORKA-001 and ORKA-002, with Phase 2 combination studies planned to begin in 2027.”
Company press release, Aug 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 26, 2026 ·
Clinical trial Reported Week 16 results from the Phase 2b EVERLAST-B trial of ORKA-001 in moderate-to-severe psoriasis. In the 600 mg group, 61% reached PASI 100 versus 0% on placebo (p<0.0001), with 86% reaching PASI 90 and IGA 0/1. Form 8-K · SEC filing · Press release
Aug 28, 2026 ·
Financing Oruka Therapeutics filed a prospectus for an at-the-market offering of up to $500,000,000 of common stock through TD Cowen as sales agent, with commissions of up to 3.0% of gross proceeds. The last reported sale price on August 20, 2026 was $104.86 per share. Form 424B5 · SEC filing
Aug 24, 2026 ·
Leadership Oruka Therapeutics appointed Todd Edwards as Chief Commercial Officer, effective August 24, 2026, with a $525,000 base salary, a $200,000 signing bonus, and option and RSU grants covering 20,000 and 100,000 shares. Form 8-K · SEC filing
Aug 21, 2026 ·
Financing Oruka Therapeutics filed a shelf registration on Form S-3 for up to $1,000,000,000 of common stock, preferred stock, depositary shares and warrants, including up to $500,000,000 of common stock under a sales agreement with TD Securities (USA) LLC as sales agent. Form S-3 · SEC filing
Aug 10, 2026 ·
Earnings Reported Q2 2026 results: cash of $1.1 billion as of June 30, 2026. R&D expenses rose to $43.3 million from $24.1 million and net loss was $41.2 million, versus $24.6 million a year earlier. EVERLAST-A Week 28 data are expected at the end of 3Q 2026. Form 8-K · SEC filing · Press release
Aug 10, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Oct 2027 · Phase 2 · Active Trial · Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis Registry primary completion date, not a results date
Oct 2028 · Phase 2 · Recruiting · ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa Registry primary completion date, not a results date
May 2030 · Phase 2 · Recruiting · An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis Registry primary completion date, not a results date
Oct 2026 · Phase 2 · Active Trial · Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis Registry date passed, readout not confirmed
Mar 2026 · Phase 2 · Active Trial · ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ORKA holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $38.7M/quarter from operations,
an estimated runway of 93.4 months at that rate (BioRadar estimate, not company guidance).
Share count 67,822,359 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ORKA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ORKA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.